Volociximab
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]
It is thought to reduce metastases. Early results show potential in renal cell cancers.
[ref needed]
References
- ↑ Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer chemotherapy and pharmacology 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731.
External links
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems |
|---|
| | Bone ("-os-", "-s(o)-") | Human ("-osu-") | |
|---|
| Humanized ("-sozu-") | |
|---|
|
|---|
| | Musculoskeletal ("-mul-") | |
|---|
| | Circulatory ("-c(i[r])-") | Human ("-ciru-") | |
|---|
| Mouse ("-ciro-") | |
|---|
| Chimeric ("-cixi-") | |
|---|
| | |
|---|
|
|---|
| | Neurologic ("-ne(u)(r)-") | Human ("-neru-") | |
|---|
| Humanized ("-nezu-"/"-neuzu-") | |
|---|
|
|---|
| | Angiogenesis inhibitor ("-anibi-") | |
|---|
| |
|
